Welcome to HCV2021!
We are excited to welcome you to the 27th International Symposium on Hepatitis C Virus and Related Viruses which will be held Virtually on July 6-9, 2021.
The International Symposium on Hepatitis C Virus and Related Viruses has been a recurring annual conference since 1994. It has become the main forum for basic science investigators working on hepatitis C virus (HCV) and related viruses. Over the past 26 years, this conference has been instrumental in developing and advancing major discoveries in the HCV field including the understanding of the virus life cycle and development of in vitro replication systems and animal models that led to the development of direct acting antivirals (DAA) that have revolutionized HCV treatment. Key discoveries in understanding the immune response and pathogenesis of HCV presented at this meeting are now the basis for ongoing vaccine development and preclinical trials. Despite this progress, basic research on HCV remains at the forefront to drive HCV elimination efforts and reduce the morbidity and mortality of the disease. Research into vaccine development, HCV pathogenesis and liver cancer following DAA treatment, novel diagnostics and sequencing approaches to track the evolution and transmission of HCV in at-risk populations are only some of the key remaining research questions.
Meeting Objective
The HCV2021 meeting will focus on the main objective of HCV elimination by bringing together Basic and Clinical investigators to discuss the remaining challenges in the HCV field and novel approaches to tackle them towards this aim. The symposium will bring together keynote lectures from outstanding senior investigators and rising stars in virology, immunology and liver disease. In addition, high quality oral and poster presentations will be selected from submitted abstracts.
Proposed Themes
- Tools for HCV Elimination: Diagnostics, Sequencing and Beyond
- Innate Immunity/Virus-Host Interaction
- Virus Life Cycle 1 (Entry and Replication)
- Virus Life Cycle 2 (Translation and Assembly)
- Adaptive Immunity
- Liver Inflammation, Viral Pathogenesis, and Carcinogenesis
- Animal Models, Organoids and Replication Systems
- Antivirals, Challenges and New Frontiers
- Vaccines
- COVID-19 and SARS-CoV-2 / HCV co-infection
We look forward to greeting you Virtually!
| Meeting Chairs | |||
|---|---|---|---|
 |
Naglaa H. Shoukry, BPharm., PhD Professor of Medicine, Université de Montréal and CanHepC Quebec, Canada |
 |
Jordan Feld, MPH, MDAssociate Professor of Medicine, University of Toronto Ontario, Canada |
 |
Daniel Lamarre, PhDPresident and CEODiuTinus ImmunoTherapeutics Inc. Cleveland, OH, USA | ||
zero-tolerance policy
The local organizing committee (LOC) of HCV2021 and the International organizing committee (IOC) of the “International Symposium on hepatitis C virus and related viruses” have a zero-tolerance policy towards harassment of any kind.
We are dedicated to providing an engaging and inclusive environment at the Symposia and any associated events including affiliated workshops, welcome receptions, and conference dinners. We expect positive, constructive and professional discussion, that values diversity and inclusion. No participant should be subjected to harassment of any kind when participating in our events.
To read the full statement, please CLICK HERE.
EQUITY, DIVERSITY, AND INCLUSION
The local organizing committee (LOC) of HCV2021 and the International organizing committee (IOC) of the “International Symposium on hepatitis C virus and related viruses” are committed to diversity, inclusiveness and equity and seek to prevent discrimination of any kind at its Symposia and related events. This includes ensuring appropriate inclusion within the program and consideration towards people of different ethnicity, genders, and career stage at its symposia and related events.
